FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465018622> ?p ?o ?g. }

• W2465018622 endingPage "8008" @default.
• W2465018622 startingPage "8008" @default.
• W2465018622 abstract "8008 Background: Lenalidomide (Rev) has markedly improved survival in patients (pts) with MM. As we gain insight into the long-term effects of this agent, concern has arisen for the possibility of SPM including MDS/AML. Clarithromycin (Biaxin), lenalidomide and dexamethasone (BiRD) was shown to be an effective regimen in symptomatic, newly diagnosed MM. Of 72 patients enrolled, 90.3% had an objective response, 38.9% a complete response (sCR/CR), and 73.6% at least a very good partial response (VGPR). This experience has been compounded by the observation of deepening responses to prolongation of Rev-based therapy beyond induction. All pts have continued to be followed. Methods: Review of all pts charts from the original study with focus on overall survival, progression of disease, time to progression, and development of SPM was completed. Pts were maintained on BiRD until progression of disease, stem cell transplant, or development of intolerable side effects. Results: Long-term follow up demonstrates an overall survival of 82.2% (95% CI 70.7, 89.5) after 4 years. Eleven pts remain on study, while 47 have received second line therapy. Evaluation of SPM in the 68 evaluable pts revealed 11 new diagnoses (incidence of 16%) after an average of 31 cycles (range 3-68) of lenalidomide (BiRd). Six were skin cancers (4 BCC, 2 SCC), 2 colon, 1 prostate, 1 pancreas and 1 metastatic melanoma. Notably, none developed MDS/AML. Mean time to SPM diagnosis was 35 months (range 5-64). Only 7/11 subjects were still on active lenalidomide therapy. Conclusions: BiRD is a highly effective regimen in newly diagnosed MM. In these treatment-naïve pts, no cases of secondary MDS/AML were seen, in contrast to reports in relapse/refractory pts who received Rev as third or fourth line therapy (Reece, Goswami ) or as post-transplant maintenance (Attal , McCarthy). Frequency of SPM is similar to 2010 SEER data for non-MM individuals of similar age. As survival in pts with MM continues to improve, so will our understanding of the long-term effects of novel agents. Design of regular cancer screening programs (derm and GI) of MM pts should be regularly implemented." @default.
• W2465018622 created "2016-07-22" @default.
• W2465018622 creator A5000554189 @default.
• W2465018622 creator A5014718917 @default.
• W2465018622 creator A5024592292 @default.
• W2465018622 creator A5028248272 @default.
• W2465018622 creator A5046945316 @default.
• W2465018622 creator A5047805762 @default.
• W2465018622 creator A5056839401 @default.
• W2465018622 creator A5061867174 @default.
• W2465018622 creator A5068215001 @default.
• W2465018622 creator A5071121646 @default.
• W2465018622 creator A5077846750 @default.
• W2465018622 creator A5082720713 @default.
• W2465018622 date "2011-05-20" @default.
• W2465018622 modified "2023-09-26" @default.
• W2465018622 title "Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM)." @default.
• W2465018622 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.8008" @default.
• W2465018622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023033" @default.
• W2465018622 hasPublicationYear "2011" @default.
• W2465018622 type Work @default.
• W2465018622 sameAs 2465018622 @default.
• W2465018622 citedByCount "10" @default.
• W2465018622 countsByYear W24650186222012 @default.
• W2465018622 countsByYear W24650186222013 @default.
• W2465018622 countsByYear W24650186222016 @default.
• W2465018622 countsByYear W24650186222018 @default.
• W2465018622 crossrefType "journal-article" @default.
• W2465018622 hasAuthorship W2465018622A5000554189 @default.
• W2465018622 hasAuthorship W2465018622A5014718917 @default.
• W2465018622 hasAuthorship W2465018622A5024592292 @default.
• W2465018622 hasAuthorship W2465018622A5028248272 @default.
• W2465018622 hasAuthorship W2465018622A5046945316 @default.
• W2465018622 hasAuthorship W2465018622A5047805762 @default.
• W2465018622 hasAuthorship W2465018622A5056839401 @default.
• W2465018622 hasAuthorship W2465018622A5061867174 @default.
• W2465018622 hasAuthorship W2465018622A5068215001 @default.
• W2465018622 hasAuthorship W2465018622A5071121646 @default.
• W2465018622 hasAuthorship W2465018622A5077846750 @default.
• W2465018622 hasAuthorship W2465018622A5082720713 @default.
• W2465018622 hasConcept C120665830 @default.
• W2465018622 hasConcept C121332964 @default.
• W2465018622 hasConcept C126322002 @default.
• W2465018622 hasConcept C141071460 @default.
• W2465018622 hasConcept C143998085 @default.
• W2465018622 hasConcept C2776063141 @default.
• W2465018622 hasConcept C2776364478 @default.
• W2465018622 hasConcept C2779609412 @default.
• W2465018622 hasConcept C2780401358 @default.
• W2465018622 hasConcept C2781413609 @default.
• W2465018622 hasConcept C61511704 @default.
• W2465018622 hasConcept C71924100 @default.
• W2465018622 hasConcept C90924648 @default.
• W2465018622 hasConceptScore W2465018622C120665830 @default.
• W2465018622 hasConceptScore W2465018622C121332964 @default.
• W2465018622 hasConceptScore W2465018622C126322002 @default.
• W2465018622 hasConceptScore W2465018622C141071460 @default.
• W2465018622 hasConceptScore W2465018622C143998085 @default.
• W2465018622 hasConceptScore W2465018622C2776063141 @default.
• W2465018622 hasConceptScore W2465018622C2776364478 @default.
• W2465018622 hasConceptScore W2465018622C2779609412 @default.
• W2465018622 hasConceptScore W2465018622C2780401358 @default.
• W2465018622 hasConceptScore W2465018622C2781413609 @default.
• W2465018622 hasConceptScore W2465018622C61511704 @default.
• W2465018622 hasConceptScore W2465018622C71924100 @default.
• W2465018622 hasConceptScore W2465018622C90924648 @default.
• W2465018622 hasIssue "15_suppl" @default.
• W2465018622 hasLocation W24650186221 @default.
• W2465018622 hasOpenAccess W2465018622 @default.
• W2465018622 hasPrimaryLocation W24650186221 @default.
• W2465018622 hasRelatedWork W1963690178 @default.
• W2465018622 hasRelatedWork W1967461244 @default.
• W2465018622 hasRelatedWork W1999964913 @default.
• W2465018622 hasRelatedWork W2013163224 @default.
• W2465018622 hasRelatedWork W2418365780 @default.
• W2465018622 hasRelatedWork W2530787370 @default.
• W2465018622 hasRelatedWork W2751497063 @default.
• W2465018622 hasRelatedWork W2980910443 @default.
• W2465018622 hasRelatedWork W4366352960 @default.
• W2465018622 hasRelatedWork W2345923217 @default.
• W2465018622 hasVolume "29" @default.
• W2465018622 isParatext "false" @default.
• W2465018622 isRetracted "false" @default.
• W2465018622 magId "2465018622" @default.
• W2465018622 workType "article" @default.